Establishing a competitive marketplace may include mandating that innovator drug companies make samples available for testing, prohibiting rebate walls and exclusionary contracts that preclude biosimilar competition, and investing in more biosimilar education targeting physicians and payers.
In U.S. Biosimilars Run Into More Roadblocks
